The Therapeutic Goods Administration is experiencing system issues linked to global Microsoft outages. Some services may be disrupted and we may take longer to respond to email and phone contact during this time.
LENCADOPA, LEVOCARBAMET, LEVODOPA/CARBIDOPA GPPL, LEVOCARBAMET, LEVODOPA/CARBIDOPA GXP, APO-LEVODOPA/CARBIDOPA, LEVODOPA/CARBIDOPA GENPAR (Generic Partners Pty Ltd)
Product name
LENCADOPA, LEVOCARBAMET, LEVODOPA/CARBIDOPA GPPL, LEVOCARBAMET, LEVODOPA/CARBIDOPA GXP, APO-LEVODOPA/CARBIDOPA, LEVODOPA/CARBIDOPA GENPAR
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
232 working days (255)
Active ingredients
levodopa / carbidopa
Registration type
New generic medicine
Indication
LEVODOPA, CARBIDOPA (tablets) is indicated for the treatment of Parkinson's disease and syndrome.